1
Jean A Setterstrom, John E Van Hamont, Robert H Reid, Elliot Jacob, Ramasubbu Jeyanthi, Edgar C Boedeker, Charles E McQueen, Daniel L Jarboe, Frederick Cassels, William Brown, Curt Thies, Thomas R Tice, F Donald Roberts, Phil Friden: Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix. The United States of America represented by the Secretary of the Army, Caroline Nash, Elizabeth Arwine, October 30, 2001: US06309669 (195 worldwide citation)

Novel burst-free, sustained release biocompatible and biodegrable microcapsules which can be programmed to release their active core for variable durations ranging from 1-100 days in an aqueous physiological environment. The microcapsules are comprised of a core of polypeptide or other biologically ...


2

3
Jean A Setterstrom, John E Van Hamont, Robert H Reid, Elliot Jacob, Ramasubbu Jeyanthi, Edgar C Boedeker, Charles E McQueen, Daniel L Jarboe, Frederick Cassels, William Brown, Curt Thies, Thomas R Tice, F Donald Roberts, Phil Friden: Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix. The United States of America represented by the Secretary of the Army, Elizabeth Arwine, January 18, 2005: US06844010 (5 worldwide citation)

Novel burst-free, sustained release biocompatible and biodegrable microcapsules which can be programmed to release their active core for variable durations ranging from 1-100 days in an aqueous physiological environment. The microcapsules are comprised of a core of polypeptide or other biologically ...


4
Daniel L Jarboe, Robert H Reid, Edgar C Boedeker, Frederick J Cassels: Oral-intestinal vaccines against diseases caused by enteropathic organisms using antigens encapsulated within biodegradable-biocompatible microspheres. The United States of America represented by the Secretary of the Army, Elizabeth Arwine, October 20, 2009: US07604811

This invention is directed to oral-intestinal vaccines and their use against diseases caused by enteropathogenic organisms using antigens encapsulated within biodegradable-biocompatible microspheres.


5
Robert H Reid, John E VanHamont, William R Brown, Edgar C Boedeker, Curt Thies: Microparticle carriers of maximal uptake capacity by both M cells and non-M cells. The United States of America represented by the Secretary of the Army, Elizabeth Arwine, March 2, 2010: USRE041157

In a solvent extraction process for preparing microspheres of a biodegradable polymer, the improvement comprising: preparing a homogenized antigen-sucrose matrix and adding a solvent to the sucrose-antigen matrix to form a solution; preparing a solution of a biodegradable polymer by adding a solvent ...


6
Edgar C Boedeker, Isaac Wyatt Byrd: -based vaccine vector and methods relating thereto, Attenuated enterohemorrhagic. STC UNM, Procopio Cory Hargreaves & Savitch, Patrric J Rawlins, May 3, 2016: US09327019

An attenuated enterohemorrhagic E. coli-based vaccine vector is disclosed. Enterotoxigenic E. coli colonization factor antigen 1 and the B subunit of E. coli heat labile toxin have been expressed in the attenuated enterohemorrhagic E. coli vector strain. Immunized animals are further protected again ...


7
Edgar C Boedeker, Frederick J Cassels, Daniel L Jarboe, Robert H Reid: Oral-intestinal vaccines against diseases caused by enteropathogenic organisms using antigens encapsulated within biodegradable-biocompatible microspheres. Nash & Titus, March 25, 2010: US20100074913-A1

This invention is directed to oral-intestinal vaccines and their use against diseases caused by enteropathogenic organisms using antigens encapsulated within biodegradable-biocompatible microspheres.


8
Edgar C Boedeker, Isaac Wyatt Byrd: Attenuated enterohemorrhagic e.coli-based vaccine vector and methods relating thereto. Stcunm, April 19, 2012: US20120093870-A1

An attenuated enterohemorrhagic E. coli-based vaccine vector is disclosed. Enterotoxigenic E. coli colonization factor antigen 1 and the B subunit of E. coli heat labile toxin have been expressed in the attenuated enterohemorrhagic E. coli vector strain. Immunized animals are further protected again ...